WO2009054454A1 - カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤 - Google Patents

カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤 Download PDF

Info

Publication number
WO2009054454A1
WO2009054454A1 PCT/JP2008/069235 JP2008069235W WO2009054454A1 WO 2009054454 A1 WO2009054454 A1 WO 2009054454A1 JP 2008069235 W JP2008069235 W JP 2008069235W WO 2009054454 A1 WO2009054454 A1 WO 2009054454A1
Authority
WO
WIPO (PCT)
Prior art keywords
signaling
regulator
active ingredient
therapeutic agent
toll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/069235
Other languages
English (en)
French (fr)
Inventor
Hiroshi Takayanagi
Masataka Asagiri
Toshitake Hirai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Tokyo Medical and Dental University NUC
Original Assignee
Nippon Chemiphar Co Ltd
Tokyo Medical and Dental University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd, Tokyo Medical and Dental University NUC filed Critical Nippon Chemiphar Co Ltd
Priority to US12/739,497 priority Critical patent/US20100331545A1/en
Priority to EP08841616A priority patent/EP2216047A4/en
Priority to JP2009538249A priority patent/JPWO2009054454A1/ja
Publication of WO2009054454A1 publication Critical patent/WO2009054454A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

【課題】ＴＬＲのシグナル伝達の調整剤を提供すること。 【解決手段】（２Ｓ，３Ｓ）－３－［［（１Ｓ）－１－イソブトキシメチル－３－メチルブチル］カルバモイル］オキシラン－２－カルボン酸モノナトリウム）などのカテプシン阻害剤を有効成分として含有する製剤をＴＬＲのシグナル伝達の調整剤、ＴＬＲのシグナル伝達が関与する疾患の治療の治療剤、Ｔｈ１７細胞の誘導が関与する疾患の治療剤、ＩＬ－６、ＩＬ－１２、ＩＬ－１７又はＩＬ－２３の産生が関与する疾患の治療剤、並びに全身性エリテマトーデス、ループス腎炎、クローン病、乾癬、又は急性散在性脳脊髄炎の治療剤として使用する。
PCT/JP2008/069235 2007-10-24 2008-10-23 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤 Ceased WO2009054454A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/739,497 US20100331545A1 (en) 2007-10-24 2008-10-23 Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
EP08841616A EP2216047A4 (en) 2007-10-24 2008-10-23 Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
JP2009538249A JPWO2009054454A1 (ja) 2007-10-24 2008-10-23 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-276937 2007-10-24
JP2007276937 2007-10-24

Publications (1)

Publication Number Publication Date
WO2009054454A1 true WO2009054454A1 (ja) 2009-04-30

Family

ID=40579556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069235 Ceased WO2009054454A1 (ja) 2007-10-24 2008-10-23 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤

Country Status (4)

Country Link
US (1) US20100331545A1 (ja)
EP (1) EP2216047A4 (ja)
JP (1) JPWO2009054454A1 (ja)
WO (1) WO2009054454A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200230251A1 (en) * 2014-08-14 2020-07-23 Friedrich-Schiller-Universitaet Jena Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects
EP3193906B1 (en) * 2014-09-18 2020-11-11 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336428A (ja) * 1993-05-27 1994-12-06 Takeda Chem Ind Ltd 免疫抑制剤
WO1996030354A1 (en) 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Epoxysuccinic acid derivatives
WO1997021694A1 (en) 1995-12-12 1997-06-19 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivatives or salts thereof, and drugs containing the same
WO1998047887A1 (en) 1997-04-18 1998-10-29 Taiho Pharmaceutical Co., Ltd. Novel epoxysuccinamide derivatives or salts thereof
WO1999011640A1 (en) 1997-09-04 1999-03-11 Nippon Chemiphar Co., Ltd. Epoxysuccinamide derivatives
JPH11263783A (ja) 1998-01-09 1999-09-28 Taisho Pharmaceut Co Ltd エポキシスクシナム酸誘導体
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
JP2000509376A (ja) * 1996-04-22 2000-07-25 マサチューセッツ インスティテュート オブ テクノロジー カテプシンｓの阻害を通しての免疫応答の抑制
WO2001049288A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
WO2001058886A1 (en) 2000-02-10 2001-08-16 Novartis Ag Dipeptide nitrile cathepsin k inhibitors
WO2001070232A1 (en) 2000-03-21 2001-09-27 Smithkline Beecham Corporation Protease inhibitors
JP2002539190A (ja) * 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規化合物および組成物
JP2003519125A (ja) * 1999-12-24 2003-06-17 エフ．ホフマン−ラ ロシュ アーゲー カテプシンｋ阻害剤としてのニトリル誘導体
WO2003053331A2 (en) 2000-11-22 2003-07-03 Smithkline Beecham Corporation Protease inhibitors
WO2003075836A2 (en) 2002-03-05 2003-09-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2003091202A1 (en) 2002-04-25 2003-11-06 Ono Pharmaceutical Co., Ltd. Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient
JP2004517918A (ja) 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
JP2004526662A (ja) * 2000-04-18 2004-09-02 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
WO2004108661A1 (en) 2003-06-04 2004-12-16 Axys Pharmaceuticals Amidino compounds as cysteine protease inhibitors
WO2005000800A1 (en) 2003-06-30 2005-01-06 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
JP2005501017A (ja) * 2001-06-08 2005-01-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆的阻害剤として有効な新規なニトリル
WO2005066180A1 (en) 2004-01-08 2005-07-21 Medivir Ab Cysteine protease inhibitors
JP2006505526A (ja) * 2002-08-22 2006-02-16 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
JP2006514004A (ja) 2002-10-30 2006-04-27 ジェネンテック・インコーポレーテッド Ｉｌ−１７産生の阻害
JP2006519768A (ja) * 2003-03-13 2006-08-31 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンｓインヒビター
JP2006520781A (ja) 2003-03-10 2006-09-14 シェーリング　コーポレイション Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
WO2006109045A2 (en) * 2005-04-09 2006-10-19 Fusion Antibodies Limited Cathepsin s antibody
WO2007025774A2 (en) 2005-09-02 2007-03-08 Glaxo Group Limited Cysteine protease inhibitors
JP2007511593A (ja) 2003-11-21 2007-05-10 セルテック アール アンド ディ リミテッド Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556853A (en) * 1993-10-29 1996-09-17 Takeda Chemical Industries, Ltd. Epoxysuccinic acid derivatives
CA2532948A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336428A (ja) * 1993-05-27 1994-12-06 Takeda Chem Ind Ltd 免疫抑制剤
WO1996030354A1 (en) 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Epoxysuccinic acid derivatives
WO1997021694A1 (en) 1995-12-12 1997-06-19 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivatives or salts thereof, and drugs containing the same
JP2000509376A (ja) * 1996-04-22 2000-07-25 マサチューセッツ インスティテュート オブ テクノロジー カテプシンｓの阻害を通しての免疫応答の抑制
WO1998047887A1 (en) 1997-04-18 1998-10-29 Taiho Pharmaceutical Co., Ltd. Novel epoxysuccinamide derivatives or salts thereof
WO1999011640A1 (en) 1997-09-04 1999-03-11 Nippon Chemiphar Co., Ltd. Epoxysuccinamide derivatives
JPH11263783A (ja) 1998-01-09 1999-09-28 Taisho Pharmaceut Co Ltd エポキシスクシナム酸誘導体
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
JP2002539190A (ja) * 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規化合物および組成物
JP2003519125A (ja) * 1999-12-24 2003-06-17 エフ．ホフマン−ラ ロシュ アーゲー カテプシンｋ阻害剤としてのニトリル誘導体
WO2001049288A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
WO2001058886A1 (en) 2000-02-10 2001-08-16 Novartis Ag Dipeptide nitrile cathepsin k inhibitors
WO2001070232A1 (en) 2000-03-21 2001-09-27 Smithkline Beecham Corporation Protease inhibitors
JP2004526662A (ja) * 2000-04-18 2004-09-02 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
JP2004517918A (ja) 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
WO2003053331A2 (en) 2000-11-22 2003-07-03 Smithkline Beecham Corporation Protease inhibitors
JP2005501017A (ja) * 2001-06-08 2005-01-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆的阻害剤として有効な新規なニトリル
WO2003075836A2 (en) 2002-03-05 2003-09-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2003091202A1 (en) 2002-04-25 2003-11-06 Ono Pharmaceutical Co., Ltd. Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient
JP2006505526A (ja) * 2002-08-22 2006-02-16 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
JP2006514004A (ja) 2002-10-30 2006-04-27 ジェネンテック・インコーポレーテッド Ｉｌ−１７産生の阻害
JP2006520781A (ja) 2003-03-10 2006-09-14 シェーリング　コーポレイション Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2006519768A (ja) * 2003-03-13 2006-08-31 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンｓインヒビター
WO2004108661A1 (en) 2003-06-04 2004-12-16 Axys Pharmaceuticals Amidino compounds as cysteine protease inhibitors
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
WO2005000800A1 (en) 2003-06-30 2005-01-06 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
JP2007511593A (ja) 2003-11-21 2007-05-10 セルテック アール アンド ディ リミテッド Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
WO2005066180A1 (en) 2004-01-08 2005-07-21 Medivir Ab Cysteine protease inhibitors
WO2006109045A2 (en) * 2005-04-09 2006-10-19 Fusion Antibodies Limited Cathepsin s antibody
WO2007025774A2 (en) 2005-09-02 2007-03-08 Glaxo Group Limited Cysteine protease inhibitors

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ASAGIRI M. ET AL.: "Cathepsin K-Dependent Toll- Like Receptor 9 Signaling Revealed inExperimental Arthritis", SCIENCE, vol. 319, no. 5863, 1 February 2008 (2008-02-01), pages 624 - 627, XP008135679 *
C.S. LI ET AL., BIOORG., MED. CHEM. LETT., vol. 16, 2006, pages 1985 - 1989
H. HEMMI ET AL., NATURE, vol. 408, 2000, pages 740
J. ROBICHAUD ET AL., J. MED. CHEM., vol. 46, 2003, pages 3709 - 3727
K. INABA ET AL., J. EXP. MED., vol. 176, 1992, pages 1693
K. SATO ET AL., NAT MED, vol. 12, 2006, pages 1410
N. KATUMUMA ET AL., FEBS LETT., vol. 458, 1999, pages 6 - 10
P. SAFTIG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 13453
R.W. MARQUIS ET AL., J. MED. CHEM., vol. 44, 2001, pages 1380 - 1395
T. OTSUKA ET AL., J. ANTIBIOT., vol. 52, 1999, pages 536 - 541
T. YASUMA ET AL., J. MED. CHEM., vol. 41, 1998, pages 4301 - 4308
TSUKUBA T. ET AL.: "Cathepsin E-deficient mice show increased susceptibility to bacterialinfection associated with the decreased expression of multiple cellsurface Toll-like receptors", JOURNAL OF BIOCHEMISTRY, vol. 140, no. 1, 2006, pages 57 - 66, XP008135678 *

Also Published As

Publication number Publication date
US20100331545A1 (en) 2010-12-30
EP2216047A4 (en) 2011-12-28
EP2216047A1 (en) 2010-08-11
JPWO2009054454A1 (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
WO2007075883A3 (en) Transdermal delivery of meptazinol
WO2007127263A3 (en) Therapeutic uses of urolithins
WO2008070268A3 (en) Pharmaceutical compositions
IL201479A0 (en) Titration of tapentadol
WO2011014661A3 (en) Liver x receptor agonists
TW200626068A (en) Active compounds for seed treatment
TW201144302A (en) 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
WO2007025613A3 (en) Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2011005595A3 (en) 2-5a analogs and their methods of use
WO2008001200A3 (en) Transdermal composition having enhanced color stability
WO2011156557A3 (en) Compounds active at the neurotensin receptor
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
IL177483A0 (en) Means for transdermal administration of nicotine
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2008135819A8 (en) Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide
HK1255438A1 (zh) 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
FR2938777B1 (fr) Catalyseur en coquille, procede de preparation et utilisation de ce catalyseur.
WO2010007522A8 (en) Rna antagonists targeting gli2
WO2006096518A3 (en) Improved gacyclidine formulations
WO2007082262A3 (en) Novel compounds
WO2007107442A3 (en) Bis1,2,3,4-tetrahydroisoquinoline derivatives and their uses as pharmaceuticals
WO2009054454A1 (ja) カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
MA31369B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
EP2096165A4 (en) NEW ALCOHOL DEHYDROGENASE, GENE FOR THE ALCOHOL DEHYDROGENASE, VECTOR, TRANSFORMANTE AND METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE ALCOHOL WITH THEREOF
WO2009037586A3 (en) Use of peptidic vasopressin receptor agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841616

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009538249

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008841616

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12739497

Country of ref document: US